AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36094611 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab (P) plus Trastuzumab (T) and Docetaxel (D)
Number of subjects: 126
Study 36094611 — intervention group
Group type: COMPARATOR
Intervention: Pertuzumab (P)
Number of subjects: 126
Study 36094733 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular group (mean serum MOR levels: 275 ± 32 pg/ml)
Number of subjects: 80
Study 36094733 — intervention group
Group type: COMPARATOR
Intervention: Luteal group (mean serum MOR levels: 254 ± 28 pg/ml)
Number of subjects: 80
Study 36094804 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Therapy (tablet-based training)
Number of subjects: 19
Study 36094804 — intervention group
Group type: COMPARATOR
Intervention: Active control (paper-and-pencil games)
Number of subjects: 19
Study 36094829 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to increase immunosuppressant adherence
Number of subjects: 3896
Study 36094839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab (350 mg every 3 weeks for up to four doses)
Number of subjects: 79
Study 36095125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-risk MDS with RS
Number of subjects: 138
Study 36095134 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention including varying presence/absence of dietary meat, fish, and sugar-sweetened beverages (SSBs)
Number of subjects: 32
Study 36095134 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention including varying presence/absence of dietary meat, fish, and SSBs
Number of subjects: 32
Study 36095141 — intervention group
Group type: EXPERIMENTAL
Intervention: Equol producers (EPs)
Number of subjects: 2958
Study 36095141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal acylcarnitine metabolites
Number of subjects: 2958
Study 36095141 — intervention group
Group type: EXPERIMENTAL
Intervention: Path analyses
Number of subjects: 2958
Study 36095315 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal computed tomography screening for adrenal tumors
Number of subjects: 25356
Study 36095315 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenocortical adenoma
Number of subjects: 25356
Study 36095315 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine testing for adenomas
Number of subjects: 25356
Study 36095315 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related prevalence of adrenal tumors
Number of subjects: 25356
Study 36095841 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib 200 mg/d for 28 days
Number of subjects: 70
Study 36095841 — intervention group
Group type: COMPARATOR
Intervention: SCS treatment
Number of subjects: 70
Study 36095849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilta-cel infusion after lymphodepletion
Number of subjects: 20
Study 36096442 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in)
Number of subjects: 103
Study 36096442 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in) in patients with ctDNA-detectable baseline ALK fusion (n=64)
Number of subjects: 103
Study 36096442 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in) in patients who progressed on alectinib (n=86)
Number of subjects: 103
Study 36096532 — intervention group
Group type: EXPERIMENTAL
Intervention: BND-22 (ILT2-blocking antibody)
Number of subjects: 0
Study 36096779 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities with both MWH and SILC (CG3)
Number of subjects: 4711
Study 36096779 — intervention group
Group type: COMPARATOR
Intervention: Communities with only MWH (CG2)
Number of subjects: 4711
Study 36096779 — intervention group
Group type: COMPARATOR
Intervention: Communities with neither MWH nor SILC (CG1)
Number of subjects: 4711
Study 36096801 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe COVID-19 pneumonia patients
Number of subjects: 284
Study 36096801 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological assessment at 12 months
Number of subjects: 284
Study 36096816 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation
Number of subjects: 0
Study 36096816 — intervention group
Group type: COMPARATOR
Intervention: Discharged directly home
Number of subjects: 0
Study 36096816 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (pre-surgery)
Number of subjects: 0
Study 36096816 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (3-months post-surgery)
Number of subjects: 0
Study 36096816 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (12-months post-surgery)
Number of subjects: 0
Study 36096816 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (36-months post-surgery)
Number of subjects: 0
Study 36096873 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT+RT
Number of subjects: 15
Study 36096873 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study 36096940 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Metacognitive Therapy (MCT), up to eight sessions delivered by a CAMHS mental health practitioner
Number of subjects: 100
Study 36096940 — intervention group
Group type: COMPARATOR
Intervention: Usual care in CAMHS (individual or group-based therapy)
Number of subjects: 100
Study 36096944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant group (hypocapnic alkalosis)
Number of subjects: 20
Study 36096944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant group
Number of subjects: 20
Study 36096944 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy, non-pregnant women)
Number of subjects: 20
Study 36096944 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 36097216 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant atezolizumab monotherapy
Number of subjects: 181
Study 36097345 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1795091 (modified formulation)
Number of subjects: 54
Study 36097345 — intervention group
Group type: COMPARATOR
Intervention: GSK1795091 (original formulation)
Number of subjects: 54
Study 36097345 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1795091 (both formulations)
Number of subjects: 54
Study 36097353 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG and fMRI
Number of subjects: 87
Study 36097353 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EEG and fMRI features
Number of subjects: 87
Study 36097353 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning algorithms (SVM and Random Forest)
Number of subjects: 87
Study 36097602 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa (enzyme replacement therapy)
Number of subjects: 6
Study 36097728 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 15785
Study 36097833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 299
Study 36097844 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine (fourth dose)
Number of subjects: 324
Study 36098121 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated HIV infection
Number of subjects: 981
Study 36098121 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative participants
Number of subjects: 981
Study 36098319 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with RSV Memphis-37 in older adults (aged 60-75 years)
Number of subjects: 33
Study 36098319 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with RSV Memphis-37 in younger adults (aged 18-55 years)
Number of subjects: 33
Study 36098320 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks)
Number of subjects: 66
Study 36098320 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab alone (240 mg every 2 weeks)
Number of subjects: 66
Study 36098320 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 66
Study 36098367 — intervention group
Group type: EXPERIMENTAL
Intervention: Varlitinib + Capecitabine (VC)
Number of subjects: 77
Study 36098367 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib + Capecitabine (LC)
Number of subjects: 77
Study 36098470 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR3680 coadministered with repaglinide
Number of subjects: 18
Study 36098470 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR3680 coadministered with bupropion
Number of subjects: 18
Study 36098502 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid sequencing (<48 hr)
Number of subjects: 2170
Study 36098502 — intervention group
Group type: COMPARATOR
Intervention: Longer-turnaround sequencing (5-10 days)
Number of subjects: 2170
Study 36098877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 2
Study 36098877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 2
Study 36098877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg or 200 mg
Number of subjects: 2
Study 36098990 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone monitoring app and wearables for 6 weeks
Number of subjects: 58
Study 36099009 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroSuitUp platform (including visual motor imagery training, robotic arms controlled by BCI, wearable robotics jacket and gloves, serious game application, augmented reality module)
Number of subjects: 0
Study 36099009 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroSuitUp platform
Number of subjects: 0
Study 36099010 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-patch 12-lead ECG (SP-ECG)
Number of subjects: 36
Study 36099010 — intervention group
Group type: COMPARATOR
Intervention: Conventional ECG (C-ECG)
Number of subjects: 36
Study 36099049 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune effector dysfunction (IED) scores derived from gene expression profiling platforms.
Number of subjects: 1896
Study 36099049 — intervention group
Group type: EXPERIMENTAL
Intervention: Senescent-like bone marrow CD8+ T cells.
Number of subjects: 1896
Study 36099049 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of ICB-unresponsive tumor microenvironment using IED expression signatures.
Number of subjects: 1896
Study 36099312 — intervention group
Group type: EXPERIMENTAL
Intervention: Pf-Pv co-infection
Number of subjects: 0
Study 36099312 — intervention group
Group type: EXPERIMENTAL
Intervention: All parasites co-infection
Number of subjects: 0
Study 36099312 — intervention group
Group type: EXPERIMENTAL
Intervention: Gametocytes co-infection
Number of subjects: 0
Study 36099312 — intervention group
Group type: EXPERIMENTAL
Intervention: Pf co-infection with Pm
Number of subjects: 0
Study 36099312 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple infections (Pf-Pv-Pm)
Number of subjects: 0
Study 36099505 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of Events Scale-revised (IES-R)
Number of subjects: 196
Study 36099505 — intervention group
Group type: EXPERIMENTAL
Intervention: Centre for Epidemiological Studies Depression Scale (CES-D)
Number of subjects: 196
Study 36099505 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L (health-related quality of life)
Number of subjects: 196
Study 36099505 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender and age analysis
Number of subjects: 196
Study 36099671 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT) for early PET non-responders (P-NR) after induction CTX
Number of subjects: 75
Study 36099671 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (CTX)
Number of subjects: 75
Study 36099671 — intervention group
Group type: EXPERIMENTAL
Intervention: PET response after induction CTX
Number of subjects: 75
Study 36100197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6
Study 36100197 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR methodology and computable phenotype
Number of subjects: 6
Study 36100197 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based tools
Number of subjects: 6
Study 36100207 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) adherence to guidelines
Number of subjects: 3562
Study 36100207 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Behavior (EB) adherence to guidelines
Number of subjects: 3562
Study 36100310 — intervention group
Group type: EXPERIMENTAL
Intervention: C-CAR088 (novel humanized anti-BCMA CAR T-cell therapy)
Number of subjects: 31
Study 36100318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa (dark chocolate) 30 g/day for 1 week
Number of subjects: 20
Study 36100318 — intervention group
Group type: COMPARATOR
Intervention: Control (Clopidogrel without cocoa)
Number of subjects: 20
Study 36100355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal nalbuphine (0.1 mg/kg)
Number of subjects: 52
Study 36100355 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nalbuphine (0.05 mg/kg)
Number of subjects: 52
Study 36100698 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone and cortisol stimulation in vitro
Number of subjects: 3
Study 36100698 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA-PCa-250 xenograft in intact mice
Number of subjects: 3
Study 36100698 — intervention group
Group type: COMPARATOR
Intervention: MDA-PCa-250 xenograft in castrated mice
Number of subjects: 3
Study 36100698 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenalectomy during castration-resistant oligometastatic disease
Number of subjects: 3
Study 36100698 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic DNA whole exome sequencing (WES)
Number of subjects: 3
Study 36100698 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC)
Number of subjects: 3
Study 36100698 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-Seq
Number of subjects: 3
Study 36100698 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid quantitation
Number of subjects: 3
Study 36100698 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable isotope tracing of organoid from MDA-PCa-250
Number of subjects: 3
Study 36100880 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Together Physician Coaching (6-month, self-paced, online, asynchronous coaching program)
Number of subjects: 17
Study 36100966 — intervention group
Group type: COMPARATOR
Intervention: Maize alone (labeled 54FeSO4)
Number of subjects: 21
Study 36100966 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize + NC T. molitor (intrinsically labeled 57Fe)
Number of subjects: 21
Study 36100966 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize + LC T. molitor (dechitinized intrinsically labeled 57Fe)
Number of subjects: 21
Study 36101477 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe periodontitis
Number of subjects: 167
Study 36101477 — intervention group
Group type: COMPARATOR
Intervention: None/mild periodontitis
Number of subjects: 167
Study 36101502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET) parameters
Number of subjects: 72
Study 36101518 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA) and immune phenotyping
Number of subjects: 755
Study 36101518 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune/inflammatory biomarkers
Number of subjects: 755
Study 36101518 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 755
Study 36101518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp-PLA2, MCP-1, and oxLDL
Number of subjects: 755
Study 36101520 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib-resistant ROS1+ NSCLC patients (CUTO28-ER cells)
Number of subjects: 105
Study 36101520 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib-resistant ROS1+ NSCLC patients (STARTRK-2 trial)
Number of subjects: 105
Study 36101520 — intervention group
Group type: COMPARATOR
Intervention: ROS1-selective inhibitors
Number of subjects: 105
Study 36101543 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) therapy
Number of subjects: 14
Study 36101543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study 36101656 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg orally
Number of subjects: 97
Study 36101656 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (HC) subjects
Number of subjects: 97
Study 36102063 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36102232 — intervention group
Group type: EXPERIMENTAL
Intervention: Large LAA orifice group
Number of subjects: 302
Study 36102232 — intervention group
Group type: COMPARATOR
Intervention: Small LAA orifice group
Number of subjects: 302
Study 36102232 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 302
Study 36102499 — intervention group
Group type: EXPERIMENTAL
Intervention: Creation of the Canadian Consortium for Research in Pediatric Surgery
Number of subjects: 0
Study 36102523 — intervention group
Group type: EXPERIMENTAL
Intervention: P4HB Mesh (Phasix Mesh)
Number of subjects: 121
Study 36102593 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy (VRT)
Number of subjects: 42
Study 36102593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 42
Study 36102707 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36102758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib, rituximab, and lenalidomide (iR2) regimen
Number of subjects: 30
Study 36103041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 259
Study 36103259 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling Circle Amplification (RCA) testing
Number of subjects: 2205
Study 36103292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (sac/val)
Number of subjects: 130
Study 36103365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing with tap water
Number of subjects: 2504
Study 36103365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing with distilled water
Number of subjects: 2504
Study 36103365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing with cooled boiled water
Number of subjects: 2504
Study 36103643 — intervention group
Group type: EXPERIMENTAL
Intervention: MTB-directed therapy (both on-label and off-label therapies)
Number of subjects: 93
Study 36103643 — intervention group
Group type: EXPERIMENTAL
Intervention: MTB-directed therapy
Number of subjects: 93
Study 36103646 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline testing combined with tumor-only sequencing
Number of subjects: 100
Study 36103646 — intervention group
Group type: COMPARATOR
Intervention: Tumor-only sequencing
Number of subjects: 100
Study 36103903 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strength improvement over time
Number of subjects: 76
Study 36103903 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance improvement over time
Number of subjects: 76
Study 36103903 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal symptoms improvement over time
Number of subjects: 76
Study 36104084 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning collaborative educational bundle (learning sessions, communication skills training, implementation support)
Number of subjects: 1395
Study 36104084 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning collaborative educational bundle
Number of subjects: 1395
Study 36104165 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised nasal continuous positive airway pressure (CPAP) level selection
Number of subjects: 12
Study 36104359 — intervention group
Group type: EXPERIMENTAL
Intervention: camrelizumab (200 mg, q2w) and apatinib (250 mg, once daily)
Number of subjects: 20
Study 36104359 — intervention group
Group type: EXPERIMENTAL
Intervention: camrelizumab and apatinib
Number of subjects: 20
Study 36104734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting state
Number of subjects: 349
Study 36104734 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial state (3 hours after consuming a fat-containing meal)
Number of subjects: 349
Study 36104795 — intervention group
Group type: EXPERIMENTAL
Intervention: Elraglusib (9-ING-41) as a single agent
Number of subjects: 1
Study 36104795 — intervention group
Group type: EXPERIMENTAL
Intervention: Elraglusib (9-ING-41) in combination with anti-PD-1 mAb
Number of subjects: 1
Study 36104795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with elraglusib and anti-PD-1 mAb
Number of subjects: 1
Study 36104795 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-PD-1 mAb)
Number of subjects: 1
Study 36104949 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anti-PD1/PD-L1 and dendritic cell (DC) therapy
Number of subjects: 9
Study 36104949 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy in mice
Number of subjects: 9
Study 36104953 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified proportional win-fractions model
Number of subjects: 0
Study 36105041 — intervention group
Group type: EXPERIMENTAL
Intervention: 3L-PEG
Number of subjects: 330
Study 36105041 — intervention group
Group type: COMPARATOR
Intervention: 4L-PEG
Number of subjects: 330
Study 36105230 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine intervention
Number of subjects: 0
Study 36105230 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 36105269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 0
Study 36105300 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training
Number of subjects: 0
Study 36105300 — intervention group
Group type: COMPARATOR
Intervention: Standard of care aerobic exercise
Number of subjects: 0
Study 36105799 — intervention group
Group type: EXPERIMENTAL
Intervention: ssCAR-T-19 cells (anti-CD19 CAR-T cells with shRNA targeting IL-6)
Number of subjects: 61
Study 36105914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib at the maximum safe starting dose (MSSD) of 10 mg bid
Number of subjects: 69
Study 36105914 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 69
Study 36105925 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely controlled mandibular positioner (RCMP) titration during in-lab sleep study
Number of subjects: 141